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Amongst 472 patients with HIV-associated cryptococcal meningitis, 16% had severe visual loss at 
presentation, of whom 46% of 4-week survivors remained severely impaired. Baseline CSF opening 
pressure ≥40 cmH20 (aOR 2.56, 95% CI 1.36-4.83, p=0.02) and fungal burden >6.0 log10Colonies/ml 




Introduction  1 
HIV-associated cryptococcal meningitis (CM) is the commonest cause of adult meningitis in sub-2 
Saharan Africa, and accounts for ~180,000 deaths/year globally[1]. In addition to headache, CM often 3 
presents with altered mental status, raised intracranial pressure (ICP) and hearing and visual loss[2], 4 
with survivors often experiencing neurological sequelae[3-5].  In CM, visual loss is usually bilateral, 5 
can be sudden or gradual in onset, occurs before or during antifungal treatment, and - especially 6 
without intervention - is frequently irreversible[3, 5, 6]. Evaluation of visual acuity in encephalopathic 7 
patients is challenging: the few CM cohorts (HIV and non-HIV) that systematically examined visual 8 
acuity report a prevalence of 33%-46% for any visual impairment (<6/6 Snellen chart), with profound 9 
visual loss (<6/60) occurring in 13% of patients[5-7].  10 
Proposed mechanisms of visual loss include direct optic nerve infiltration by cryptococci 11 
(demonstrated on autopsy as well as tissue biopsy), inflammatory arachnoiditis, or optic nerve 12 
compression through raised ICP or a more localised optic nerve compartment syndrome[5], with both 13 
fungal burden and raised ICP implicated in its pathophysiology[3, 8]. Prior, small retrospective cohorts 14 
(<100 patients) suggested that high fungal burden (cerebrospinal fluid (CSF) cryptococcal antigen 15 
titre>1024) or raised ICP (CSF opening pressure(OP) >30cm H20) are associated with visual loss in CM, 16 
but have been too small to undertake multivariable analyses[3, 6]. Here we report on the prevalence, 17 
risk factors and reversibility of visual loss in a large prospective CM patient multi-country cohort in 18 
sub-Saharan Africa[9].  19 
 20 
  21 
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Methods  22 
Anonymised data from the ACTA (Advancing Cryptococcal Meningitis Treatment in Africa, ISCRTN 23 
45035509) trial formed the dataset for this pre-planned sub-study[9]. Between 2013 and 2016, 678 24 
adults with HIV CM were randomised to oral fluconazole plus flucytosine or amphotericin B-based 25 
therapy for one or two weeks. Patients had protocol-specified lumbar punctures (LPs) on day 1, 7 and 26 
14 with OP measurements and therapeutic CSF drainage according to guidelines[10].  27 
Visual acuity (VA) was measured at baseline (<3 days from enrolment) and at 4 weeks using the 28 
standardised logMAR chart in surviving patients whose conscious level permitted assessment. The 29 
score, ranging from 0 (able to read all letters on the smallest line) to 1.375 (unable to read any letters), 30 
was recorded for each eye. Those unable to read any letters were assessed for finger counting, hand 31 
movement and light perception. Those without light perception were considered blind. Patients were 32 
classified into 6 categories: 1. Near-normal vision (score<0.5), 2. Moderate visual loss (score ≥0.5 but 33 
<1.0), 3. Finger counting (score ≥1.0 and able to count fingers), 4. Hand motion perception, 5. Light 34 
perception, or 6. No light perception. When VA varied between the left and right eye (9.3%, 44/472), 35 
data for the worst eye was analysed. Patients did not routinely undergo CT brain or fundoscopy to 36 
assess for papilloedema or other ocular pathology. 37 
Data were analyzed using Stata v15 (StataCorp, USA), using Kruskal-Wallis tests for continuous 38 
variables, chi-squared tests for categorical variables and quantile regression to test for trend across 39 
the 6 visual acuity categories. Based on proposed pathophysiological mechanisms, univariable and 40 
multivariable logistic regression was used to investigate the association between baseline visual loss 41 
and CSF white cell count (WCC), OP and fungal burden, adjusted a priori for age. Sex, CD4 count and 42 
ART status (naïve or exposed) were not associated with visual loss and no other measured variables 43 
were hypothesised to confound the relationship.  For analysis of the association between VA, CSF OP 44 
and fungal burden, VA was dichotomised into near-normal/moderate vision (categories 1 and 2) and 45 
severe visual loss (categories 3-6), similar to definitions in [4].  46 
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To assess impact of antifungal therapy and therapeutic LPs on reversibility of visual impairment, rate 47 
of clearance of infection, number of LPs performed, total CSF volume removed and change in OP over 48 
2 weeks’ treatment was compared between those with repeat measurements at 4 weeks in whom 49 
acuity deteriorated and those who improved; and in those that remained severe vs improved from 50 
severe.  51 
Patient consent statement 52 
Written informed consent was obtained from all participants in ACTA.  Ethical approval was granted 53 
by the London School of Hygiene and Tropical Medicine Research Ethics Committee and by national 54 
research ethics committees and regulatory bodies in Malawi, Zambia, Cameroon and Tanzania. 55 
  56 
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Results  57 
Baseline data 58 
Of 678 ACTA participants, VA was measured in 472 (69.6%) at baseline. 75 patients (15.9%) had severe 59 
visual loss with 20 (4%) classed as blind. One fifth (15/75) of those with severe visual loss also reported 60 
hearing loss.  61 
 62 
Overall, 206 (47.1%) patients had raised baseline ICP (OP≥25cm H20) and median fungal burden was 63 
4.9 log10colonies/ml (IQR: 3.7-5.8) (Supplementary Table 1). C neoformans was the predominant 64 
species causing CM in this African cohort (337/382 sequenced isolates). Due to difficulties in 65 
measuring VA in unconscious patients, the VA cohort had less abnormal mental status (GCS<15) 66 
(12.5% vs 50.5%, p<0.001) and lower median OP (19 vs 25cmH20, p<0.001), but no significant 67 
differences in median fungal burden (4.9 vs 5.1 log10colonies/ml, p=0.74), compared to the entire trial 68 
cohort.  69 
 70 
Association between severe baseline visual loss, opening pressure and fungal burden 71 
Across 6 categories from near-normal to blind, decreasing visual acuity was associated with both 72 
increased OP and higher fungal burden at baseline (p=0.02 and p<0.008, respectively) (Fig 1a and b). 73 
High OP and fungal burden were also associated, with 55 (25.6%) patients with fungal burden above 74 
the median (≥4.9 log10 colonies/ml) also experiencing high OP (>40cm H20)- compared to 33 (15.4%) 75 
with lower fungal burden (p=0.009).  76 
In multivariable analyses, age; baseline CSF pressure <25 cm vs ≥40cmH20: aOR 2.56 (95% CI 1.36-77 
4.83, p=0.02) and fungal burden (<5 vs >6.0log10Colonies/ml: aOR 3.01 (95% CI 1.58-5.7, p= 0.003) 78 
were independently associated with severe visual loss (Table 1).  There was no association between 79 
baseline CNS inflammation (CSF WCC>10x109/L) and visual loss on either univariable or multivariable 80 




Changes in visual acuity over time 83 
Paired visual acuity data were available for 336/472 (71.2%) patients at baseline and week 4. Of these 84 
171 (50.9%) had normal vision, 128 (38.1%) had moderate vision and 37 (11.0%) had severe visual loss 85 
at baseline.  Death before follow-up was the main reason for missing data at 4 weeks (98/136, 72.1%).  86 
VA remained unchanged over time for 210 (62.5%) patients. No significant differences were observed 87 
in rate of clearance of infection, number of LPs performed, total volume of CSF removed and change 88 
in OP over the first 2 weeks of treatment between the group remaining the same, those in whom VA 89 
deteriorated (n=51, 15.2%) and those that improved (n=75, 22.3%) (p>0.1, all comparisons 90 
Supplementary Table 2).   91 
Of 37 (11%) patients with severe visual loss at baseline, 12 (32.4%) improved to near-normal, 8 (21.6%) 92 
improved to moderate and 17 (46.0%) remained severe. Again, there were no significant differences 93 
in the above parameters between patients remaining severely impaired and those improving 94 
(Supplementary Table 3), though numbers for comparison were low.  95 
  96 
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Discussion  97 
This prospective study within a large African trial is the first to demonstrate an independent 98 
association of both fungal burden and raised ICP, in addition to age, with visual loss at presentation 99 
with HIV-CM. At presentation, 16% of patients had severe visual loss and 4% were blind: in those with 100 
repeat measurements at 4 weeks, following fungicidal treatment regimens and aggressive 101 
management of raised ICP, 54% of patients with severe baseline visual loss improved to near-normal 102 
or moderate vision,  while 46% remained severely impaired.  103 
In a case series comprising both HIV-infected and uninfected patients (n=49), the authors proposed 104 
dichotomous mechanisms of visual loss, optic neuritis due to fungal infiltration accounting for early 105 
rapid visual loss, and optic nerve compression due to raised ICP accounting for a slower onset. 106 
Interventions aimed at reducing ICP were the only ones associated with any success[3]. In a study of 107 
immunocompetent adults with C gattii meningitis, where ICP was not consistently measured or 108 
managed, 37% of 57 survivors remained blind, compared to 5% in our cohort[6]. The uniformity of our 109 
cohort, in terms of use of fungicidal regimens and pressure management, may not have permitted us 110 
to show a significant impact of rate of clearance or changes in pressure-related parameters on 111 
reversibility of visual loss. 112 
 113 
The most comprehensive mechanistic study of visual loss in HIV-CM[5] observed frequent optic nerve 114 
conduction and visual field defects compatible with raised ICP, and no evidence of optic neuritis on 115 
MRI, presenting evidence for an optic nerve compartment syndrome, caused by cryptococcal plugging 116 
of channels between the intracranial and the peri-optic subarachnoid space, as an additional cause of 117 
optic nerve dysfunction in CM[8].  In practise, these mechanisms may well overlap[8]: our prior 118 
work[2] and findings from this study suggest a relationship between fungal burden and raised pressure 119 
at the highest extremes of each. These two factors likely converge in an individual patient, possibly 120 
more susceptible due to neuroanatomical variation, rendering them either temporarily or- in the 121 
absence of intervention- permanently visually impaired. 122 
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  123 
Limitations of our cohort include the lack of visual assessment at baseline or reversibility at 4 weeks 124 
in the sickest of patients who subsequently die, possibly underestimating the prevalence of visual loss. 125 
We did not capture self-reported visual impairment predating CM onset which may have impacted on 126 
baseline VA, nor were we able to exclude other conditions that can impair vision in this advanced HIV 127 
cohort (e.g. CMV retinitis). Nonetheless, our findings underscore the importance of interventions 128 
targeted at both fungal burden and raised ICP in mitigating visual loss, and underline the need for 129 
continued efforts towards earlier diagnosis and treatment of CM, given that, almost half of those with 130 
severe impairment failed to improve despite fungicidal regimens and aggressive management of 131 
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Figure 1: a. Box plot (median, IQR, range) of baseline Cerebrospinal fluid (CSF) opening pressure by 
visual acuity group at presentation.  b. Box plot of baseline fungal burden by visual acuity group at 
presentation. NN-Near normal; ML- moderate loss; CF- Counting fingers; LP- Light perception; NV- 












Table 1. Univariable and multivariable analysis for the association between age, baseline CSF 







Visual Acuity at CM 
presentation (no. (%)) 
  
 
















Age         
<50 year 356 (89.7) 41 (10.3) 1   1   
≥50 years 61 (81.3) 14 (18.7) 1.99 (1.03-3.87) 0.04 2.47 (1.22 - 5.05) 0.04 
CSF opening 
pressure (cmH20)  
        
<25 200 
(86.6.0) 
31 (13.4) 1   1   
25-39 98 (85.2) 17 (14.8) 1.12 (0.59-2.12)  1.28 (0.66-2.47)  
≥40 66 (72.5) 25 (27.5) 2.44  (1.35-4.43) 0.003 2.56 (1.36-4.83) 0.02 
Fungal Burden 
(log10colonies/ml)  
        
<5.0                       206 (88.4) 27 (11.6) 1   1   
5.0-5.9                              113 (84.3) 21 (15.7) 1.42 (0.77- 2.62)  1.31 (0.69 - 2.47)  
>6.0   62 (70.5) 26 (29.5) 3.20 (1.74 -5.88) 0.001 3.01 (1.58 - 5.70) 0.003 
White cell count  
(x 109/L) 
        
<10 249 (82.2) 54 (17.8) 1   1   
≥10 126 (86.3) 20 (13.7) 0.73  (0.42 - 1.28) 0.27 0.70 (0.39 – 
1.25) 
0.22 
*Adjusted for each variable in the table         OR: Odds ratio        CI: Confidence Interval         CSF: Cerebrospinal fluid 
 
 
